Los Angeles Capital Management’s Atea Pharmaceuticals AVIR Stock Holding History

Los Angeles Capital Management’s Portfolio AVIR Stock Details AVIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-77,304	Closed	-$253K	–	2405
2025 Q4	$253K	Hold	77,304	–	–	﹤0.01%	1153
2025 Q3	$224K	Buy	77,304 +43,229	+127%	+$148K	﹤0.01%	1234
2025 Q2	$123K	Buy	+34,075	New	+$102K	﹤0.01%	1240
2023 Q1	–	Sell	-175,048	Closed	-$842K	–	1169
2022 Q4	$842K	Sell	175,048 -2,100	-1%	-$10.6K	﹤0.01%	748
2022 Q3	$1.01M	Sell	177,148 -24,326	-12%	-$186K	0.01%	694
2022 Q2	$1.43M	Sell	201,474 -30,451	-13%	-$208K	0.01%	615
2022 Q1	$1.67M	Buy	+231,925	New	+$1.57M	0.01%	587

Other funds holding AVIR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Los Angeles Capital Management's AVIR Position: Q1 2026 in Review

Los Angeles Capital Management sold out of Atea Pharmaceuticals (AVIR) in Q1 2026, closing a stake of 77,304 shares — an estimated $253K sold.

Los Angeles Capital Management first reported a position in AVIR in Q1 2022 and held it in 7 quarters. The position peaked at $1.67M in Q1 2022. 127 funds tracked by Wall St. Rank hold AVIR as of Q1 2026.

Los Angeles Capital Management reported no remaining Atea Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Los Angeles Capital Management sold 77,304 Atea Pharmaceuticals shares in Q1 2026, an estimated $253K.
Los Angeles Capital Management first reported a position in Atea Pharmaceuticals in Q1 2022 and held it in 7 quarters.
Los Angeles Capital Management's Atea Pharmaceuticals position peaked at $1.67M in Q1 2022.
127 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q1 2026.

Based on Los Angeles Capital Management's 13F filing for Q1 2026, filed 8 May 2026.